Our

Immuno Oncology

products will replace multiple checkpoint inhibitors with a single, standalone product, delivered orally.

 

LAPIX-IO Pipeline

IO updates pipline.PNG

Immuno Oncology

Why We’re Different.

 
 
Icon-5.png
 

LAPIX-IO activates immune cells.

Current approved I/O therapies only block ligand/receptor interaction. LAPIX-IO out-competes TIM’s natural ligand and commits T-cells to an active cytotoxic T lymphocyte pathway.

 
Icon-4.png
 

LAPIX-IO down-regulates multiple checkpoints.

Multi-checkpoint inhibition is an emerging trend in oncology as evident from FDA’s approval of Opdivo® (IV) + Yervoy® (IV) for Patients with Metastatic Non-Small Cell Lung Cancer.

Targeting TIM receptors with LAPIX-IO leads to downregulation of multiple checkpoints at once including PD-1, CLTA4, KLRG-1, and TIM-3.

 
icon-3.png
 

LAPIX-IO can be taken orally.

LAPIX-IO candidate molecules are orally bioavailable and have shown efficacy in murine models after oral administration